共 50 条
- [21] Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab JOURNAL OF CROHNS & COLITIS, 2022, 16 : I391 - I391
- [22] Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice JOURNAL OF CROHNS & COLITIS, 2019, 13 : S307 - S308
- [23] Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab JOURNAL OF CROHNS & COLITIS, 2022, 16 : I391 - I391
- [24] Therapeutic drug monitoring of infliximab induction therapy in inflammatory bowel disease. PHARMACOTHERAPY, 2017, 37 (06): : E57 - E57
- [25] Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (04): : 580 - 585
- [27] Proactive Therapeutic drug monitoring of Infliximab, but not HLA-DQA1*05, predicts clinical outcome in inflammatory bowel disease JOURNAL OF CROHNS & COLITIS, 2024, 18 : I597 - I597
- [28] Durability of Infliximab Is Associated With Disease Extent in Children With Inflammatory Bowel Disease JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2016, 62 (06): : 867 - 872
- [30] Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (10): : 2029 - 2031